ISRCTN88597330已完成2 期
A single centre phase II study of interleukin-1 receptor antagonist in the treatment of severe traumatic brain injury
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Severe traumatic brain injury
- •2. Aged 16 - 65 years, either sex
- •3. Abnormal computed tomography (CT) scan requiring sedation, paralysis, ventilation and multi-modality monitoring as part of clinical care
排除标准
- •1. Head injury unlikely to survive 5 days, e.g. bilaterally fixed dilated pupils
- •2. Follow up not possible
- •3. Not suitable for insertion of cranial access device, e.g. bleeding diathesis
- •4. Immunosuppression
- •5. Severe renal insufficiency
- •6. Pregnancy/nursing mothers
- •7. Known hypersensitivity to E. Coli derived products
- •8. Adminstration of live vaccine
研究者
相似试验
进行中（未招募）
1 期
A single centre phase II study of Interleukin 1 receptor antagonist in the treatment of severe Traumatic Brain Injury - Interleukin-1 Receptor Antagonist in Severe Traumatic Brain InjuryEUCTR2005-005707-42-GBCambridge University Hospitals NHS Foundation Trust and University of Cambridge20
进行中（未招募）
1 期
BLOC-ICH; Could a new treatment improve recovery for patients who have had an intracerebral haemorrhageintracerebral haemorrhageMedDRA version: 20.0 Level: LLT Classification code 10022753 Term: Intracerebral haemorrhage System Organ Class: 100000004852EUCTR2018-000249-38-GBniversity of Manchester80
尚未招募
4 期
A Clinical Trial to test a turmeric based product (Curenext) in treating gum disease.CTRI/2011/05/001767Shaju Jacob P20
进行中（未招募）
1 期
Study of immunotherapy for treatment of patients with malignancies of the thymus (type B3 thymoma and thymic carcinoma) and already treated with chemotherapyEUCTR2015-005504-28-NLEuropean Organisation for Research and Treatment of Cancer80
进行中（未招募）
1 期
Study of immunotherapy for treatment of patients with malignancies of the thymus (type B3 thymoma and thymic carcinoma) and already treated with chemotherapyEUCTR2015-005504-28-GBEuropean Organisation for Research and Treatment of Cancer80